Bevacizumab is currently being explored for use in early breast cancer, as neoadjuvant treatment in the NSABP B40 study, in TRN breast cancer (BEATRICE study), and in HER2-positive disease as adjuvant treatment (BETH study). The gene discussed is ERBB2; the disease is breast cancer.